SFDA Speeds Up Release Of Vaccines To Quake-Hit Regions
This article was originally published in PharmAsia News
Due to the urgent needs of earthquake victims, China's State FDA has, for the second time, adjusted the procedure for release of blood products and vaccines to speed up the distribution of relief supplies. SFDA and vaccine manufacturers will synchronize the quality inspection and approval of badly needed vaccine and blood products that have been produced but are awaiting approval, as well as products still being churned out. These include tetanus immunoglobulin, human albumin, cholera toxin B subunit vaccine, hepatitis A vaccine, Japanese B encephalitis vaccine, diphtheria and tetanus combined vaccine, tetanus vaccine and hemorrhagic fever vaccine. (Click here for more - Chinese Language)
You may also be interested in...
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.
A proposed rule released last month by the US Department of Health and Human Services is the Trump administration’s “latest attempt to sabotage HHS programs,” wrote Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities. See what the policy expert said about it in her blog post here.
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.